Australia - englanti - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - piperacillin sodium, quantity: 2.085 g (equivalent: piperacillin, qty g); tazobactam sodium, quantity: 268.3 mg (equivalent: tazobactam, qty mg) - injection, powder for - excipient ingredients: - piperacillin/tazobactam kabi is indicated in the treatment of serious bacterial infections caused by susceptible strains of beta-lactamase producing organisms in the conditions listed below: 1. lower respiratory tract infections. 2. urinary tract infections (complicated and uncomplicated). 3. intra-abdominal infections. 4. skin and skin structure infections. 5. bacterial septicaemia. 6. gynaecological infections.,,children under the age of 12 years:,in hospitalised children aged 2 to 12 years, piperacillin/tazobactam kabi injection is indicated for the treatment of serious intra-abdominal infections. it has not been evaluated in this indication for paediatric patients below the age of 2 years.,while piperacillin/tazobactam kabi injection is indicated only for the conditions listed above, it may be used as a single agent in the treatment of mixed infections caused by piperacillin susceptible and beta-lactamase producing piperacillin-resistant organisms. appropriate culture and susceptibility tests should be performed before treatment in order to identify organisms causing infection to determine their susceptibilities to piperacillin/tazobactam. therapy with piperacillin/tazobactam, however, may be initiated before results of such tests are known when there is a reason to believe the infection may involve any of the beta-lactamase producing organisms listed above; however, once these results become available, appropriate therapy should be continued.,in serious infections, presumptive therapy with piperacillin/tazobactam kabi may be initiated before susceptibility test results are available.,combination therapy with piperacillin/tazobactam kabi and aminoglycosides may be used in the treatment of serious infections caused by pseudomonas aeruginosa. both drugs should be used in full therapeutic doses. as soon as results of culture and susceptibility tests become available, antimicrobial therapy should be adjusted.

Singapore - englanti - HSA (Health Sciences Authority)

fresenius kabi (singapore) pte ltd - hematology - the anticoagulant solution acd-a is intended for use with blood cell separators (apheresis).

Singapore - englanti - HSA (Health Sciences Authority)

fresenius kabi (singapore) pte ltd - general hospital - the agilia sp pca syringe pump is primarily intended for pca (patient-controlled analgesia) therapy, for the administration of analgesic drugs under the patient’s or the clinician’s control. the agilia sp pca syringe pump can also be used for general infusions on adults, pediatrics, and neonatal patients for the intermittent or continuous delivery of parenteral fluids (such as solutions, colloids, parenteral nutrition), medications (such as diluted drugs, chemotherapy, anesthesia drugs), blood and blood derivatives, and medications through clinically accepted routes of administration. it is intended for use by trained healthcare professionals in clinical healthcare facilities. in pca therapy, it is also intended for use by the patient in order to self administer doses of analgesic agent, after receiving appropriate training and instructions from the clinical staff. it is not intended for use during pre-hospital medical ground transportation.

Singapore - englanti - HSA (Health Sciences Authority)

fresenius kabi (singapore) pte ltd - general hospital - the agilia vp mc large volume infusion pump is a peristaltic pump intended for use on adults, pediatrics, and neonatal patients for the intermittent or continuous delivery of parenteral fluids (such as solutions, colloids, parenteral nutrition), medications (such as diluted drugs, chemotherapy, anesthesia drugs), blood and blood derivatives, and medications through clinically accepted routes of administration.

Singapore - englanti - HSA (Health Sciences Authority)

fresenius kabi (singapore) pte ltd - hematology - the amicore apheresis system is an automated blood cell separator intended for use in the collection of blood components. the amicore apheresis system is indicated to collect: 1. platelets pheresis, leukocytes reduced (single or double units). 2. platelets pheresis, leukocytes reduced, platelet additive solution (single or double units) -- (p6r8884 kit code only) 3. plasma (p6r8884 kit code only)

Singapore - englanti - HSA (Health Sciences Authority)

fresenius kabi (singapore) pte ltd - ear, nose & throat - it is intended solely for enteral feeding in continuous application.

Singapore - englanti - HSA (Health Sciences Authority)

fresenius kabi (singapore) pte ltd - ear, nose & throat - enteral feeding pump for continuous and bolus application.

Singapore - englanti - HSA (Health Sciences Authority)

fresenius kabi (singapore) pte ltd - general hospital - sterile, single use back check valves for use with gravity or pressure infusion equipment. the device is for parallel infusions is used in infusion therapy with infusion sets and extension lines or as a connector at indwelling venous cannulas and peripheral venous catheters.

Singapore - englanti - HSA (Health Sciences Authority)

fresenius kabi (singapore) pte ltd - hematology - medical device for leukocyte reduction from platelet concentrates

Singapore - englanti - HSA (Health Sciences Authority)

fresenius kabi (singapore) pte ltd - hematology - medical device for leukocyte reduction from platelet concentrates (pools from 4 to 6 single units or buffy coats or an equivalent unit from apheresis).